Dipyridamole for preventing stroke and other vascular events in patients with vascular disease

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2007, Pages

  De Schryver, E L L M ^b   Algra, Ale ^a   Van Gijn, J ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b NONE

Author keywords

Anticoagulants therapeutic use ; Aspirin therapeutic use ; Cerebrovascular disorders mortality; *prevention control ; Dipyridamole *therapeutic use ; Fibrinolytic agents therapeutic use ; Ischemic attack, transient complications

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; DIPYRIDAMOLE; PLACEBO; SULFINPYRAZONE;

ARTERY DISEASE; BLEEDING; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG RELEASE; DRUG SAFETY; DRUG URINE LEVEL; FOLLOW UP; HEART DEATH; HEART INFARCTION; HUMAN; MONOTHERAPY; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; REVIEW; VASCULAR DISEASE;

EID: 42949114082     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD001820.pub3     Document Type: Review

References (60)

1. ACCSG 1985 {published and unpublished data} The American-Canadian Co-operative Study Group. Persantine aspirin trial in cerebral ischemia. Stroke 1983;14:99-103.
2. *The American-Canadian Co-operative Study Group. Persantine aspirin trial in cerebral ischemia. Part II: Endpoint results. Stroke 1985;16:406-15.
3. AICLA 1983a {published and unpublished data} *Bousser MG, Eschwege E, Haguenau M, Lefaucconnier JM, Thibult N, Touboul D, et al."AICLA" controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. Stroke 1983;14:5-14.
4. AICLA 1983b {published and unpublished data} Bousser MG, Eschwege E, Haguenau M, Lefaucconnier JM, Thibult N, Touboul D, et al."AICLA" controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. Stroke 1983;14:5-14.
5. Atlanta 1967 {published and unpublished data} Sbar S, Schlant RC. Dipyridamole in the treatment of angina pectoris. A double-blind evaluation. JAMA 1967;201:865-7.
6. Becker 1967 {published and unpublished data} Becker MC. Angina Pectoris: a double blind study with dipyridamole. Journal of the Newark Beth Israel Hospital 1967;18:88-94.
7. Caneschi 1985a {published data only} Caneschi S, Bonaventi C, Finzi F. Ischemic cerebrovascular disease: treatment with various anti-platelet aggregation drugs. Clinical follow-up of 80 patients (22-34 months). Minverva Medica 1985;76:1933-43.
8. Caneschi 1985b {published data only} Caneschi S, Bonaventi C, Finzi F. Ischemic cerebrovascular disease: treatment with various anti-platelet aggregation drugs. Clinical follow-up of 80 patients (22-34 months). Minverva Medica 1985;76:1933-43.
9. Chairangsarit 2005 {published data only} Chairangasarit P, Sithinamsuwan P, Niyasom S, Udommongkol C, Nidhinandana S, Suwantamee J. Comparison between aspirin combined with dipyridamole versus aspirin alone within 48 hours after ischemic stroke event for prevention of recurrent stroke and improvement of neurological function: a preliminary study. Journal of the Medical Association of Thailand 2005;88 Suppl 3:148-54.
10. DAMAD 1989a {published and unpublished data} The DAMAD Study Group. Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy. A multicenter randomized controlled clinical trial. Diabetes 1989;38:491-8.
11. DAMAD 1989b {published and unpublished data} The DAMAD Study Group. Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy. A multicenter randomized controlled clinical trial. Diabetes 1989;38:491-8.
12. ESPRIT 2006 {published data only} De Schryver ELLM. Design of ESPRIT: an international randomized trial for secondary prevention after non-disabling cerebral ischaemia of arterial origin. European/Australian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT) group. Cerebrovascular Diseases 2000;10(2):147-50.
13. *The ESPRIT Study Group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT); randomised controlled trial. Lancet 2006;367:1665-73.
14. ESPS-1 1990 {published and unpublished data} ESPS Group. European Stroke Prevention Study. Stroke 1990;21:1122-30.
15. ESPS-2 1997a {published and unpublished data} Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. Journal of Neurological Sciences 1996;143:1-13.
16. The ESPS-2 Group. European Stroke Prevention Study 2. Efficacy and safety data. Journal of Neurological Sciences 1997;151 Suppl:S1-S77.
17. ESPS-2 1997b {published and unpublished data} Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. Journal of Neurological Sciences 1996;143:1-13.
18. ESPS-2 1997c {published and unpublished data} Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. Journal of Neurological Sciences 1996;143:1-13.
19. ESPS-2 1997d {published and unpublished data} Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. Journal of Neurological Sciences 1996;143:1-13.
20. Gent-AMI 1968 {published and unpublished data} Gent AE, Brook CG, Foley TH, Miller TN. Dipyridamole: a controlled trial of its effect in acute myocardial infarction. BMJ 1968;4:366-8.
21. German Fistula 1992 {unpublished data only} The profylaxis of thrombosis in new arteriovenous dialysis shunts in the arm by low-dose acetylsalicylic acid and dipyridamole. Unpublished work 1992.
22. Hess 1985a {published and unpublished data} Hess H, Mietaschk A, Deichsel G. Drug-induced inhibition of platelet function delays progression of peripheral occlusive arterial disease. A prospective double-blind arteriographically controlled trial. Lancet 1985;1:415-9.
23. Hess 1985b {published and unpublished data} Hess H, Mietaschk A, Deichsel G. Drug-induced inhibition of platelet function delays progression of peripheral occlusive arterial disease. A prospective double-blind arteriographically controlled trial. Lancet 1985;1:415-9.
24. Igloe 1970 {published data only} Igloe MC. Treatment of angina pectoris with dipyridamole: a double-blind study. Journal of the American Geriatric Society 1970;18:233-41.
25. Libretti 1986 {published and unpublished data} Catalano M, Libretti A. Dipyridamole combined with acetylsalicylic acid versus acetylsalicylic acid alone in the treatment of peripheral vascular disease. International Angiology 1984;3:321-2.
26. *Libretti A, Catalano M. Treatment of claudication with dipyridamole and aspirin. Monographs on Atherosclerosis 1986;14:207-9.
27. Mayo-B 1989 {published and unpublished data} *Chesebro JH. Antiplatelet therapy in coronary disease progression reduced infarction and new lesion formation. Circulation 1989;80 Suppl II:266.
28. Misra 1983 {published and unpublished data} Misra NP, Bhargava RK, Manoria PC. Comparative trials of sulphinpyrazone and aspirin + dipyridamole in acute myocardial infarction. Current Therapeutic Research 1983;34:558-66.
29. PARIS-I 1980a {published and unpublished data} The Persantine-Aspirin Reinfarction Study (PARIS) research group. The Persantine-Aspirin reinfarction study. Circulation 1980;62:449-61.
30. PARIS-I 1980b {published and unpublished data} The Persantine-Aspirin Reinfarction Study (PARIS) research group. The Persantine-Aspirin reinfarction study. Circulation 1980;62:449-61.
31. PARIS-II 1986 {published and unpublished data} Klimt CR, Knatterud GL, Stamler J, Meier P. Persantine-Aspirin Reinfarction Study. Part II. Secondary coronary prevention with persantine and aspirin. Journal of the American College of Cardiology 1986;7:251-69.
32. PISA 2001 {published data only} Picano E, on behalf of the PISA study group. Dipyridamole in chronic stable angina pectoris; a randomized, double blind, placebo-controlled, parallel group study. European Heart Journal 2001;22:1785-93.
33. Prandoni 1991 {published and unpublished data} Prandoni P, Milani L, Barbiero M, Cardaioli P, Sanson A, Barbaresi F, et al.Treatment of unstable angina with dipyridamole combined with low doses of aspirin. A multicenter pilot double-blind controlled study. Minerva Cardioangiologica 1991;39:267-73.
34. Rome 1986 {published data only} Gentile R, Lagana B, Calcagni S, Sorgia MC, Baratta L. Efficacy of platelet-inhibiting agents in the prevention of reinfarction in smoker patients. Proceedings of X World Congress of Cardiology, Washington, USA. 1986:302 (Abstract 1724).
35. Schoop-I 1983a {published and unpublished data} Schoop W. Long-term results with conservative treatment of occlusive arteriopathies. Internist 1984;25:429-33.
36. *Schoop W, Levy H, Schoop B, Gaentzsch A. Experimentelle und klinische Studien zu der sekundären Prävention der peripheren Arteriosklerose. In: BollingerA, RhynerK editor(s). Thrombozytenfunktionshemmer, Wirkungsmechanismen, Dosierung und praktische Anwendung. New York: Georg Thieme Verlag Stuttgart, 1983:49-58.
37. Schoop W, Levy R. Prevention of peripheral arterial occlusive disease with antiaggregants. Thrombosis and Haemostasis 1983;50:137.
38. Schoop-I 1983b {published and unpublished data} Schoop W, Levy H, Schoop B, Gaentzsch A. Experimentelle und klinische Studien zu der sekundären Prävention der peripheren Arteriosklerose. In: BollingerA, RhynerK editor(s). Thrombozytenfunktionshemmer, Wirkungsmechanismen, Dosierung und praktische Anwendung. New York: Georg Thieme Verlag Stuttgart, 1983:49-58.
39. Sreedhara 1994a {published and unpublished data} Sreedhara R, Himmelfarb J, Lazarus JM, Hakim RM. Anti-platelet therapy in graft thrombosis: results of a prospective, randomized, double-blind study. Kidney International 1994;45:1477-83.
40. Sreedhara 1994b {published and unpublished data} Sreedhara R, Himmelfarb J, Lazarus JM, Hakim RM. Anti-platelet therapy in graft thrombosis: results of a prospective, randomized, double-blind study. Kidney International 1994;45:1477-83.
41. Sreedhara 1994c {published and unpublished data} Sreedhara R, Himmelfarb J, Lazarus JM, Hakim RM. Anti-platelet therapy in graft thrombosis: results of a prospective, randomized, double-blind study. Kidney International 1994;45:1477-83.
42. Sreedhara 1994d {published and unpublished data} Sreedhara R, Himmelfarb J, Lazarus JM, Hakim RM. Anti-platelet therapy in graft thrombosis: results of a prospective, randomized, double-blind study. Kidney International 1994;45:1477-83.
43. Stoke 1969 {published and unpublished data} Acheson J, Danta G, Hutchinson EC. Controlled trial of dipyridamole in cerebral vascular disease. BMJ 1969;i:614-5.
44. Toulouse 1982a {published and unpublished data} Guiraud-Chaumeil B, Rascol A, David J, Boneu B, Clanet M, Bierme R. Prévention des récidives des accidents vasculaires cérébraux ischémiques par les anti-agrégants plaquettaires. Résultats d'un essai thérapeutique controlé de 3 ans. Revue Neurologique (Paris) 1982;138:367-85.
45. Toulouse 1982b {published and unpublished data} Guiraud-Chaumeil B, Rascol A, David J, Boneu B, Clanet M, Bierme R. Prévention des récidives des accidents vasculaires cérébraux ischémiques par les anti-agrégants plaquettaires. Résultats d'un essai thérapeutique controlé de 3 ans. Revue Neurologique (Paris) 1982;138:367-85.
46. VA Co-op 1986 {published and unpublished data} Colwell JA, Bingham SF, Abraira C, Anderson JW, Comstock JP, Kwaan HC, et al. Veterans Administration Cooperative Study on antiplatelet agents in diabetic patients after amputation for gangrene: II. Effects of aspirin and dipyridamole on atherosclerotic vascular disease rates. Diabetes Care 1986;9:140-8.
47. White 1995 {published and unpublished data} White HD, French JK, Hamer AW, Brown MA, Williams BF, Ormiston JA, et al.Frequent reocclusion of patent infarct-related arteries between 4 weeks and 1 year: effects of antiplatelet therapy. Journal of the American College of Cardiology 1995;25:218-23.
48. Wirecki 1967 {published and unpublished data} Wirecki M. Treatment of angina pectoris with dipyridamole: a long-term double blind study. Journal of Chronic Diseases 1967;20:139-45.
49. Algra 1996 Algra A, van Gijn J. Aspirin at any dose above 30 mg offers only modest protection after cerebral ischaemia. Journal of Neurology Neurosurgery and Psychiatry 1996;60:197-99.
50. Algra 1999a Algra A, Koudstaal PJ, van Gijn J. Secondary prevention after cerebral ischaemia of presumed arterial origin: is aspirin still the touchstone?. Journal of Neurology Neurosurgery and Psychiatry 1999;66:557-9.
51. Algra 1999b Algra A, van Gijn J. Cumulative meta-analysis of aspirin efficacy after cerebral ischaemia of arterial origin. Journal of Neurology Neurosurgery and Psychiatry 1999;66:255.
52. APT I 1994 Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - 1: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
53. ATT 2002 Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
54. Deeks 2005 Deeks JJ, Higgins JPT, Altman DG. Analysing and presenting results. Cochrane Handbook of Systematic Review of Interventions 4.2.5 [Updated May 2005]; Section 8.8. In: HigginsJPT, GreenS editor(s). The Cochrane Library, Issue 3, 2005. Chichester, UK: John Wiley & Sons Ltd, 2005.
55. Dutch TIA Trial 1991 The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. New England Journal of Medicine 1991;325:1261-6.
56. FitzGerald 1987 FitzGerald GA. Modern drug therapy: dipyridamole. New England Journal of Medicine 1987;316:1247-57.
57. Kaye 1990 Kaye J. A trial to evaluate the relative roles of dipyridamole and aspirin in the prevention of deep vein thrombosis in stroke patients. Boehringer Ingelheim Internal Report 1990.
58. UK-TIA Trial 1991 UK-TIA Study Group. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. Journal of Neurology Neurosurgery and Psychiatry 1991;54:1044-54.
59. Warlow 1992 Warlow C. Secondary prevention of stroke. Lancet 1992;339:724-7.
60. De Schryver 2006 De Schryver ELLM, Algra A, van Gijn J. Dipyridamole for preventing stroke and other vascular events in patients with vascular disease. Cochrane Database of Systematic Reviews 2006, Issue 2.Art. No.: CD001820. DOI:10.1002/14651858.CD001820.pub3.